Navigation Links
ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
Date:2/9/2010

LEUVEN, Belgium, February 9 /PRNewswire-FirstCall/ --

- Paper Examines the Potential of Microplasmin to Improve the Treatment of a Range of Back of the Eye Diseases

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.

A paper entitled "A Placebo-Controlled Trial of Microplasmin Intravitreous Injection to Facilitate Posterior Vitreous Detachment Before Vitrectomy" has been published online ahead of print in Ophthalmology. This publication covers the Phase II trial (MIVI III) with microplasmin, with the objective of evaluating the efficacy and safety of intravitreal microplasmin in facilitating the separation of the vitreous from the retina. The separation of the vitreous from the retina is used to treat a range of back of the eye disorders and is achieved currently via a surgical procedure called a vitrectomy.

The paper showed that the highest dose of microplasmin (125microg) led to a greater likelihood of induction and progression of PVD than placebo injection. Moreover, patients in this dose group had a statistically significant improvement in visual acuity at the 35-day timepoint when compared to placebo. Also, the trial showed that patients receiving microplasmin were significantly more likely not to require vitrectomy surgery to resolve their underlying disease.

The results outlined in the article highlight that microplasmin could be a pot
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics NV - Q3 2009 Business Update
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
4. ThromboGenics NV Announces Business Update and Half Year Results 2009
5. ThromboGenics NV: Business Update
6. ThromboGenics Announces Business Update and 2008 Full Year Results
7. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
8. ThromboGenics N.V.: Business Update
9. ThromboGenics Announces Half Year Results 2008
10. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
11. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Robert Harman, DVM, Founder and CEO ... proud to announce the relaunch of his highly informative blog, ... series called “ What are Stem Cells ?” Dr. ... straightforward foundation in the basics of stem cell therapy so ... right type of treatment when considering regenerative medicine. , A ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... July 10, 2014  Kainos Capital, a firm specializing ... announced that it has acquired the Slim-Fast brand from ... business. Terms of the transaction were not disclosed. ... replacement business that markets ready-to-drink shakes, powders, bars and ... and in the United Kingdom ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY), ... therapeutic products for the treatment of cancer, today announced ... year end 2009 financial results on Wednesday, August 12, ... markets. Following the release, Oncothyreon,s management expects to discuss ...
... HARBIN, China, Aug. 6 /PRNewswire-Asia-FirstCall/ -- ... "the Company") (Nasdaq: CSKI ), a leading,fully ... of China ("PRC"), today announced the appointment of Mr.,William ... Board of Directors,("the Board") effective August 4, 2009. Mr. ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ... endocrine therapy and oncology, today announced that its President ... overview at the upcoming Canaccord Adams 29th Annual Global ... p.m. (eastern time) at the Intercontinental Hotel in Boston. ...
Cached Biology Technology:China Sky One Medical, Inc. Appoints New Independent Director 2China Sky One Medical, Inc. Appoints New Independent Director 3
(Date:7/10/2014)... genus Axinaea belongs to the large, mainly tropical ... ca. 5000 species in the family rely on bees for ... by other insects or vertebrates. The flowers of Axinaea ... flowers and the petals of the different species are pink, ... out based on the contrasting colours of their bulbous appendages. ...
(Date:7/10/2014)... Imagine the open ocean as a microbial megacity, teeming ... drop of water, hundreds of types of bacteria can ... of these ocean microbes have their own daily cyclesnot ... to wake up, commute, work, and eat at the ... sun. Light-loving photoautotrophsbacteria that need solar energy to help ...
(Date:7/10/2014)... company housed at NJIT,s business incubator, received a $1.4 ... surgeons will use to staunch bleeding during brain surgery. ... site, and the natural bio-polymer solutions in the gel ... 30 seconds. , The gel can shorten an ... into less time for the patient,s skull to be ...
Breaking Biology News(10 mins):Novel type of bird pollination mechanism discovered in South America 2New research finds ocean's most abundant organisms have clear daily cycles 2New research finds ocean's most abundant organisms have clear daily cycles 3A start-up at NJIT develops bleeding-control gel for brain surgery 2
... you ever met a cat that doesn't go crazy over ... the world don't respond to it at all, according to ... of Chemical & Engineering News, the weekly newsmagazine published by ... Catnip sensitivity is inherited, says Carolyn M. McDaniel, a veterinarian ...
... Florida researchers say they are a step closer to ... cancers before symptoms become apparent. , The findings, currently ... Sciences, involve introducing molecularly engineered strands of DNA into ... burst after they adhere to cancer proteins. , ...
... the gene responsible for controlling a first key step in ... in the journal Nature tomorrow (Thursday 27 October 2005). , ... take place once a sperm enters an egg, giving it ... reproducing animals. , The absence or mutation of this gene ...
Cached Biology News:Many cats unaffected by catnip, C&EN reports 2Scientists closer to new cancer detection method 2Scientists closer to new cancer detection method 3Scientists unpick genetics of first 15 minutes of life 2
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
Donor Goat Serum...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
Biology Products: